Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sa(...)

AstraZeneca may have a second chronic obstructive pulmonary disease treatmentan after a study showed an experimental combination of lung drugs improved breathing function. Photograph: Jason Alden/Bloomberg

AstraZeneca said an experimental combination of lung drugs improved breathing function, potentially giving the UK firm its second chronic obstructive (...)

The acquisition is the latest in a spate of big pharma deals this year as many companies are strengthening their portfolios as old drugs go generic

AbbVie is to buy Pharmacyclics for about $21 billion, giving it access to what is expected to be one of the world’s top-selling cancer drugs and expan(...)

GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company’s vaccines business and divesting its cancer drugs portfolio to Novartis

GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers.G(...)

Pfizer has offered $90 per share in cash for Hospira Photograph: Reuters

Pharmaceutical giant Pfizer has offered to buy Hospira for about $15 billion (€13bn) to boost its portfolio of generic injectible drugs and biosimilar(...)

Joe Kaeser, chief executive of German industrial group Siemens, addresses a news conference ahead of the annual shareholder meeting in Munich on Tuesday. Siemens missed first-quarter profit forecasts and announced management overhauls at its power and gas and healthcare divisions. (Photograph: Michael Dalder/Reuters)

US equity-index futures fell with European stocks as results by companies from Caterpillar to Microsoft and Siemens disappointed investors. Greek bon(...)

Dublin index heavyweight CRH added 1.17 per cent to close at €19.83

European markets rose as oil company gains helped to counterbalance a sharp fall in Swiss equities sparked by the country’s national bank decision to(...)

Scott McCauley, associate scientist at the Gilead Sciences, makes human proteins at the Gilead laboratory in Foster City, California. Photograph: David Paul Morris/Bloomberg

Anne Strange was too ill to dance at the evening reception when her daughter, Debbie, married in November but just being there was enough. The 63-year(...)

Switzerland’s Novartis has high hopes for an experimental chronic heart failure drug. Photograph: Reuters/Arnd Wiegmann

An experimental heart failure medicine from Novartis that previously showed it reduced death and hospitalisations also curtailed worsening of symptoms(...)

Virgin America president David Cush in the New York Stock Exchange yesterday before the company’s shares’ first day of trading. Photograph: Michael Loccisano/Getty Images

European stocks were little changed as slides in healthcare and commodity stocks offset gains in media companies.Eurostat, the EU’s official number c(...)